Splenectomy for immune thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.

BACKGROUND

Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by autoantibody-mediated ADAMTS-13 deficiency. Historically, splenectomy was used for multiply relapsing iTTP in clinical remission to lessen risk of relapse and as treatment for plasma-refractory or plasma-dependent iTTP.

OBJECTIVES

To evaluate the effectiveness of splenectomy on relapse in relapsing iTTP and on remission in plasma-refractory and palsma-dependent iTTP.

METHODS

We conducted a systematic review and meta-analysis of 2 questions related to splenectomy for iTTP: (1) in patients with relapsing iTTP, what is the effect of splenectomy on the iTTP relapse rate? (2) In patients with plasma-refractory or plasma-dependent iTTP, what proportion of patients achieve clinical remission after splenectomy? Three electronic databases (Embase, PubMed, and Scopus) were searched for keywords related to thrombotic thrombocytopenic purpura and splenectomy, and screening was completed following PRISMA guidelines.

RESULTS

Twenty-three studies were included, representing 62 patients (with 205.8 years of follow-up) who underwent splenectomy for relapsing iTTP and 57 patients (with 173.9 years of follow-up; not reported in 3 studies) who underwent splenectomy for plasma-refractory/dependent iTTP. In patients who underwent splenectomy for relapsing iTTP, there were 1.80 (95% CI, -2.66 to -0.95) fewer iTTP episodes annually after splenectomy compared with before splenectomy. For patients who underwent splenectomy for plasma-refractory/dependent iTTP, the proportion of patients achieving clinical remission was 0.87 (95% CI, 0.76-0.93). Only 2 studies included any patients who received rituximab.

CONCLUSION

There is low-quality evidence to support the use of splenectomy for multiply relapsing iTTP to decrease relapse rate and for plasma-refractory/dependent iTTP to achieve remission, noting that most of the evidence precedes the routine use of rituximab in iTTP.